{"entity":{"id":"nct07463235","kind":"trial","name":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","aka":[],"tldr":"A phase 3 trial of Cabergoline in Pituitary tumours, run by University of Sao Paulo General Hospital, now recruiting.","summary":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas is a phase 3 interventional study registered as NCT07463235 by University of Sao Paulo General Hospital, with 70 participants planned, started 2026-03-04 and due to reach its primary completion in 2027-08-20. Interventions recorded: Cabergoline, Cabergoline. Conditions recorded: Prolactinoma, Prolactin Excess.\n\nLinked to the drug Cabergoline because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07463235","url":"https://clinicaltrials.gov/study/NCT07463235"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pituitary-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":["cabergoline"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07463235","phase":"3","setting":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","sponsor":"University of Sao Paulo General Hospital","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07463235/","neighbours":{"cancer":[{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"}],"drug":[{"id":"cabergoline","kind":"drug","name":"Cabergoline","route":"/drugs/cabergoline/"}]}}